ALK-Abello A/S 2006 AR2
The report highlights ALK-Abelló's first year as an independently listed pharmaceutical company for the 2005/06 fiscal year. A major milestone was the European approval and launch of GRAZAX®, the world's first tablet-based vaccine against grass pollen allergy. Financially, the company's revenue increased by 22% to DKK 1,489 million, with organic growth at 9%. ALK-Abelló also acquired full ownership of its German sales subsidiary ALK-Scherax and expanded its clinical pipeline to include tablet vaccines for house dust mite and ragweed allergies. Environmental performance showed a slight increase in resource consumption due to new production facilities, while maintaining compliance with all environmental regulations.
Company: ALK-Abello A/S
Sector: Manufacturing
Country: Denmark
Year: 2006
Type: AR2
Pages: 84
ALK-Abello A/S
The report highlights ALK-Abelló's first year as an independently listed pharmaceutical company for the 2005/06 fiscal year. A major milestone was the European approval and launch of GRAZAX®, the world's first tablet-based vaccine against grass pollen allergy. Financially, the company's revenue increased by 22% to DKK 1,489 million, with organic growth at 9%. ALK-Abelló also acquired full ownership of its German sales subsidiary ALK-Scherax and expanded its clinical pipeline to include tablet vaccines for house dust mite and ragweed allergies. Environmental performance showed a slight increase in resource consumption due to new production facilities, while maintaining compliance with all environmental regulations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2006
Reporting Period
Sep 1, 2005 - Aug 31, 2006
Fiscal Year
2006
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Employees